Analysts have been eager to weigh in on the Healthcare sector with new ratings on aTyr Pharma (LIFE – Research Report) and Axcella Health (AXLA – Research Report).
aTyr Pharma (LIFE)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on aTyr Pharma today and set a price target of $35.00. The company’s shares closed last Thursday at $2.17, close to its 52-week low of $2.00.
According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on aTyr Pharma is a Strong Buy with an average price target of $21.00.
See today’s best-performing stocks on TipRanks >>
Axcella Health (AXLA)
H.C. Wainwright analyst Ed Arce downgraded Axcella Health to Hold today. The company’s shares closed last Thursday at $0.65.
According to TipRanks.com, Arce is a 3-star analyst with an average return of
Currently, the analyst consensus on Axcella Health is a Strong Buy with an average price target of $6.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LIFE:
- aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- aTyr Pharma reports Q3 EPS (46c), consensus (46c)
- aTyr Pharma to Present at Upcoming Investor Conferences
- aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
- aTyr Pharma to Present at the Jefferies London Healthcare Conference
